What is ctDNA testing and should Triple-Negative Breast Cancer patients get it

Understanding ctDNA Testing for Triple-Negative Breast Cancer

What is ctDNA Testing?

ctDNA stands for circulating tumor DNA — essentially, pieces of DNA from your cancer cells that are floating in your bloodstream. Think of it as a "liquid biopsy" — a blood test that can detect cancer-related genetic material without needing a tissue biopsy.

Here's how it works:

• Cancer cells naturally shed DNA fragments into the bloodstream
• A blood sample is drawn and analyzed using specialized sequencing technology
• The lab looks for specific genetic mutations or patterns that match your tumor
• Results can show whether cancer DNA is present, how much is there, and sometimes how your cancer is responding to treatment

Why ctDNA Testing Matters for TNBC Patients

For triple-negative breast cancer (TNBC) specifically, ctDNA testing has several important applications:

1. Detecting Minimal Residual Disease (MRD)

This is the most clinically useful application right now. After surgery or initial treatment, ctDNA testing can detect tiny amounts of cancer DNA still circulating — sometimes before imaging scans can see anything. According to recent clinical evidence, this early detection can help identify patients at higher risk of recurrence.

2. Monitoring Treatment Response

ctDNA levels can drop significantly when treatment is working, sometimes showing response 8 weeks earlier than standard imaging (according to Guardant360 Response data). This gives your oncologist earlier feedback on whether your current therapy is effective.

3. Detecting Treatment Resistance

If ctDNA levels start rising during treatment, it may signal that your cancer is becoming resistant to your current therapy — allowing your doctor to consider switching approaches sooner.

---

Current Clinical Evidence for TNBC

The medical literature shows growing support for ctDNA in TNBC:

According to NCCN Guidelines for Breast Cancer, circulating tumor DNA testing is increasingly recognized as valuable for:

• Assessing treatment response in metastatic disease
• Detecting minimal residual disease after initial treatment
• Identifying patients who may benefit from additional or modified therapy

Important context from recent webinars: Dr. [removed] Lopez-Correa, MD, PhD (a breast cancer specialist and patient advocate) emphasized that ctDNA testing should be part of the future of cancer care, particularly for early detection and monitoring. She noted that for TNBC patients specifically, comprehensive genomic testing — including liquid biopsy options — can inform treatment decisions.

One specific test mentioned in clinical studies is Signatera (a tumor-informed ctDNA test), which has been studied in TNBC populations for minimal residual disease monitoring. The NeXT Personal test and RaDaR test also have validation in TNBC cohorts.

---

Should YOU Get ctDNA Testing? Key Questions to Ask Your Oncologist

Not every TNBC patient needs ctDNA testing at every stage. Here are specific questions to discuss with your care team:

1. "Given my TNBC diagnosis and stage, would ctDNA testing help guide my treatment decisions right now?"

2. "Would ctDNA testing after my initial treatment help detect recurrence earlier than imaging alone?"

3. "Are there specific ctDNA tests you recommend, and would my insurance cover them?"

4. "If ctDNA testing shows minimal residual disease, what would that mean for my treatment plan?"

5. "What are the limitations of ctDNA testing I should understand?" (For example, a negative ctDNA result doesn't guarantee no cancer is present, and a positive result needs clinical context.)

---

Important Limitations to Understand

According to NCCN Guidelines, ctDNA testing has important caveats:

• False negatives are possible — a negative test doesn't guarantee absence of disease
• Timing matters — results are most meaningful at specific points (like after surgery or during treatment)
• Low tumor fraction — sometimes there isn't enough ctDNA in the blood to detect, especially in early-stage disease
• Interpretation requires expertise — results need to be understood in the context of your complete clinical picture, imaging, and symptoms

---

The Bottom Line for TNBC Patients

ctDNA testing is NOT yet standard of care for all TNBC patients, but it's increasingly being used in clinical practice for:

• ✅ Monitoring treatment response during therapy
• ✅ Detecting minimal residual disease after initial treatment
• ✅ Identifying early recurrence signals
• ✅ Guiding decisions about additional therapy

Cost and insurance coverage remain barriers — many ctDNA tests are not yet fully covered by insurance, though coverage is expanding. Some patients choose to pay out-of-pocket for these tests when they believe the information will guide important treatment decisions.

---

Next Steps

1. Ask your oncologist if ctDNA testing is appropriate for your specific TNBC situation and stage
2. Understand the specific test being recommended (Signatera, NeXT Personal, RaDaR, Guardant360 Response, etc.) and what it measures
3. Clarify the cost and whether your insurance will cover it
4. Get a clear explanation of what results would mean for your treatment plan

According to NCCN Guidelines for Breast Cancer and recent expert consensus, the key is ensuring that any testing — including ctDNA — is integrated into a comprehensive treatment strategy rather than ordered in isolation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.